InnoCare Pharma Limited (HKG:9969)
Hong Kong · Delayed Price · Currency is HKD 13.11
+0.71 (5.73%)
At close: Mar 27, 2026
InnoCare Pharma Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -440.63 | -631.26 | -886.59 | -64.55 |
Depreciation & Amortization | 95.59 | 88.15 | 67.48 | 33.08 |
Other Amortization | 11.54 | 11.23 | 0.93 | 0.63 |
Loss (Gain) From Sale of Assets | - | - | - | 0 |
Asset Writedown & Restructuring Costs | 0.12 | 0.02 | - | - |
Loss (Gain) From Sale of Investments | -6.26 | -5.57 | -6.46 | -6.7 |
Loss (Gain) on Equity Investments | - | - | 9.71 | 0.6 |
Stock-Based Compensation | -10.79 | 65.1 | 129.48 | 126.44 |
Provision & Write-off of Bad Debts | 1.5 | 0.27 | - | - |
Other Operating Activities | 1.88 | 49.17 | 195.01 | -40.75 |
Change in Accounts Receivable | -63.34 | -194.53 | -82.65 | -45.15 |
Change in Inventory | 47.65 | -42.46 | -52.12 | -8.04 |
Change in Accounts Payable | -2.8 | -5.61 | 34 | 79.08 |
Change in Unearned Revenue | - | - | -8.75 | 17.19 |
Change in Other Net Operating Assets | - | - | 34.42 | 75.22 |
Operating Cash Flow | -365.55 | -665.49 | -565.55 | 167.06 |
Capital Expenditures | -78.23 | -254.65 | -227.24 | -169.77 |
Sale of Property, Plant & Equipment | 0 | 0.01 | - | 0.02 |
Cash Acquisitions | - | 1.15 | - | - |
Sale (Purchase) of Intangibles | - | - | -143.09 | -1.44 |
Investment in Securities | 1,056 | 795.85 | -1,529 | -1,638 |
Other Investing Activities | 133.75 | 118.71 | 173.34 | 79.57 |
Investing Cash Flow | 1,111 | 661.06 | -1,726 | -1,730 |
Long-Term Debt Issued | 1,185 | 33.8 | 325 | 50 |
Total Debt Issued | 1,185 | 33.8 | 325 | 50 |
Long-Term Debt Repaid | -990.41 | -28.98 | -21.78 | -14.92 |
Total Debt Repaid | -990.41 | -28.98 | -21.78 | -14.92 |
Net Debt Issued (Repaid) | 194.91 | 4.82 | 303.23 | 35.08 |
Issuance of Common Stock | 18.5 | 9.95 | 2,923 | 2,527 |
Repurchase of Common Stock | -13.35 | -6.3 | - | - |
Common Dividends Paid | -362.93 | -1.15 | - | - |
Other Financing Activities | -122.73 | -6.01 | -131.95 | -17.74 |
Financing Cash Flow | -285.59 | 1.31 | 3,095 | 2,545 |
Foreign Exchange Rate Adjustments | 16.92 | 25.7 | 139.9 | -45.3 |
Net Cash Flow | 476.9 | 22.58 | 942.5 | 936.6 |
Free Cash Flow | -443.78 | -920.14 | -792.79 | -2.71 |
Free Cash Flow Margin | -43.96% | -124.59% | -126.76% | -0.26% |
Free Cash Flow Per Share | -0.26 | -0.54 | -0.54 | -0.00 |
Cash Interest Paid | - | - | 3.26 | 2.53 |
Cash Income Tax Paid | 89.25 | 58.78 | - | - |
Levered Free Cash Flow | -664.21 | -777.19 | -236.95 | 35.82 |
Unlevered Free Cash Flow | -643.09 | -755.19 | -226.29 | 37.47 |
Change in Working Capital | -18.49 | -242.6 | -75.1 | 118.3 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.